Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 12/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262019 | 1.00 | MKNK2 (0.53) | MKNK2EGFRFYNSRCDAPK3 | |
| SCHEMBL7060640 | 0.94 | ABCG2 (0.54) | MKNK2EGFRFYNSRCDAPK3 | |
| SCHEMBL3243687 | 0.76 | EGFR (0.59) | EGFRFYNSRCDAPK3MAP4K4 | |
| SCHEMBL1262022 | 0.75 | MKNK2 (0.54) | MKNK2EGFRFYNSRCDAPK3 | |
| SCHEMBL7086916 | 0.75 | CYP1A2 (0.43) | EGFRMAP4K4PIM1PRKACAMAPK8 | |
| SCHEMBL7086914 | 0.75 | CYP1A2 (0.43) | EGFRMAP4K4PIM1PRKACAMAPK8 | |
| SCHEMBL28412816 | 0.71 | EGFR (0.71) | MKNK2EGFRDAPK3MAP4K4ABL1 | |
| Acrylamide SCHEMBL4278962 | 0.69 | EGFR (0.70) | EGFRFYNSRCDAPK3MAP4K4 | |
| SCHEMBL30512 | 0.66 | EGFR (0.66) | EGFRFYNSRCDAPK3MAP4K4 | |
| SCHEMBL5717630 | 0.66 | LMNA (0.73) | KDM4EMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3050880-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-8461166-B2 | Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-8198266-B2 | Use of an EGFR antagonist for the treatment of glomerolonephritis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-7879861-B2 | 4-N-(3-bromophenyl)-6-N-(2-chloroethyl)quinazoline-4,6-diamine, capable of both inhibiting epidermal growth factor receptors and damaging DNA; antitumor and antiproliferative agents | MCGILL UNIVERSITY (CA) | 2011-02-01 | — | — | US | disclosed |
| WO-2010076764-A1 | IRREVERSIBLE EGFR INHIBITOR COMPOUNDS WITH ANTIPROLIFERATIVE ACTIVITY | UNIVERSITA' DEGLI STUDI DI PARMA (IT) | 2010-07-08 | — | — | WO | disclosed |
| US-20100104558-A1 | Use of an EGFR Antagonist for the Treatment of Glomerolonephritis | INSERM (INETITUT NATIONAL DE LA SANTE ET LA RECHERCHE MEDICALE ) (FR) | 2010-04-29 | — | — | US | disclosed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| EP-2077842-A2 | USE OF AN EGFR ANTAGONIST FOR THE TREATMENT OF GLOMEROLONEPHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-07-15 | — | — | EP | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| WO-2008053270-A2 | USE OF AN EGFR ANTAGONIST FOR THE TREATMENT OF GLOMEROLONEPHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-05-08 | — | — | WO | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
| WO-2007062459-A1 | SELECTIVE KINASE INHIBITORS BASED ON PYRIDINE SCAFFOLD | CYTOPIA RESEARCH PTY LTD (AU) | 2007-06-07 | — | — | WO | disclosed |
| EP-1366027-B1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | UNIV MCGILL (CA) | 2006-09-20 | — | — | EP | disclosed |
| US-20060003970-A1 | Novel combi-molecules having EGFR and DNA targeting properties | MCGILL UNIVERSITY (CA) | 2006-01-05 | — | — | US | disclosed |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | QIU, QIYU | 2004-05-06 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104558-A1 | Use of an EGFR Antagonist for the Treatment of Glomerolonephritis | EGFR, GCGR, PTPRJ | MKNK2 2045/4885EGFR 1/4885FYN 51/4885 |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | MKNK2 596/4885EGFR 1/4885FYN 459/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | MKNK2 3607/4885EGFR 406/4885FYN 2021/4885 |
| US-20060003970-A1 | Novel combi-molecules having EGFR and DNA targeting properties | EGFR, PCNA, ERBB2 | MKNK2 2007/4885EGFR 1/4885FYN 2548/4885 |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | LCK, CHUK, CSK | MKNK2 306/4885EGFR 293/4885FYN 38/4885 |
| US-20080207613-A1 | Selective Kinase Inhibitors | LCK, CHUK, CSK | MKNK2 306/4885EGFR 293/4885FYN 38/4885 |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | EGFR, PCNA, ERCC2 | MKNK2 673/4885EGFR 1/4885FYN 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.